Full Press Release Details
1Exhibit 99.1 CATALYST BIOSCIENCES Corporate Overview 18 June 2020 1
Nasdaq: CBIO Forward looking statements Various important factors could
cause actual results or events to differ This presentation includes forward-looking statements that involve materially, including, but not limited to, the risk that the risk that trials substantial risks and uncertainties. All statements included in
this and studies may be delayed as a result of the COVID-19 virus and presentation, other than statement of historical facts, are forward- other factors, that trials may not have satisfactory outcomes, that looking statements. Examples of such
statements include, but are potential adverse effects may arise from the testing or use of MarzAA not limited to, potential markets for MarzAA, DalcA and CB 2782- or DalcA, including the generation of antibodies, which has been PEG, potential
benefits of subcutaneous dosing, potential use of observed in patients treated with DalcA, that clinical trials will take MarzAA as a subcutaneous therapy for patients with hemophilia A longer than anticipated to be completed, that costs required to
or B with inhibitors, treatment of bleeding, Factor VII deficiency, develop or manufacture the Company's products will be higher than Glanzmann's Thrombasthenia and other bleeding disorders, anticipated, that Biogen will discontinue
development of CB 2782- potential use of DalcA as a subcutaneous therapy for patients with PEG, competition and other factors that affect our ability to establish hemophilia B, potential benefits of CB 2679d-GT as gene therapy, collaborations on
commercially reasonable terms and other risks the use of engineered proteases to treat diseases, including dAMD, described in the "Risk Factors" section of the Company's annual by mediating the complement cascade, clinical trial
results, plans for report on Form 10-K filed with the Securities and Exchange a registrational trial for MarzAA and a Phase 1/2 trial in Factor VII Commission on February 20, 2020, and the Company's quarterly deficiency, Glanzmann's
Thrombasthenia and treatment of bleeding report on Form 10-Q filed on May 11, 2020, and in other filings with in Hemlibra subjects in Q4 2020, plans to declare development the Securities and Exchange Commission. The Company does not candidates for
CB 2679d-GT and in the complement program in Q4 assume any obligation to update any forward-looking statements, 2020, and potential milestone and royalty payments from Biogen. except as required by law. Actual results or events could differ
materially from the plans, expectations and projections disclosed in these forward-looking statements. 2 catalystbiosciences.comNasdaq: CBIO Forward looking statements Various important factors could cause actual results or events to differ This
presentation includes forward-looking statements that involve materially, including, but not limited to, the risk that the risk that trials substantial risks and uncertainties. All statements included in this and studies may be delayed as a result
of the COVID-19 virus and presentation, other than statement of historical facts, are forward- other factors, that trials may not have satisfactory outcomes, that looking statements. Examples of such statements include, but are potential adverse
effects may arise from the testing or use of MarzAA not limited to, potential markets for MarzAA, DalcA and CB 2782- or DalcA, including the generation of antibodies, which has been PEG, potential benefits of subcutaneous dosing, potential use of
observed in patients treated with DalcA, that clinical trials will take MarzAA as a subcutaneous therapy for patients with hemophilia A longer than anticipated to be completed, that costs required to or B with inhibitors, treatment of bleeding,
Factor VII deficiency, develop or manufacture the Company's products will be higher than Glanzmann's Thrombasthenia and other bleeding disorders, anticipated, that Biogen will discontinue development of CB 2782- potential use of DalcA as
a subcutaneous therapy for patients with PEG, competition and other factors that affect our ability to establish hemophilia B, potential benefits of CB 2679d-GT as gene therapy, collaborations on commercially reasonable terms and other risks the use
of engineered proteases to treat diseases, including dAMD, described in the "Risk Factors" section of the Company's annual by mediating the complement cascade, clinical trial results, plans for report on Form 10-K filed with the
Securities and Exchange a registrational trial for MarzAA and a Phase 1/2 trial in Factor VII Commission on February 20, 2020, and the Company's quarterly deficiency, Glanzmann's Thrombasthenia and treatment of bleeding report on Form
10-Q filed on May 11, 2020, and in other filings with in Hemlibra subjects in Q4 2020, plans to declare development the Securities and Exchange Commission. The Company does not candidates for CB 2679d-GT and in the complement program in Q4 assume
any obligation to update any forward-looking statements, 2020, and potential milestone and royalty payments from Biogen. except as required by law. Actual results or events could differ materially from the plans, expectations and projections
disclosed in these forward-looking statements. 2 catalystbiosciences.com
Nasdaq: CBIO Essential Medicines - Superior Outcomes Late-Stage
Asset Hemophilia Complement SQ MarzAA (FVIIa) IVT Anti-C3 Dry AMD SQ Marzeptacog alfa CB 2782-PEG (activated) SQ Dalcinonacog MarzAA (FVIIa) alfa - DalcA (FIX) Factor IX Gene Therapy SQ Systemic Phase 3 in 2020 Complement Factor Xa Inhibitors
Protease Engineering Platform 3 catalystbiosciences.comNasdaq: CBIO Essential Medicines - Superior Outcomes Late-Stage Asset Hemophilia Complement SQ MarzAA (FVIIa) IVT Anti-C3 Dry AMD SQ Marzeptacog alfa CB 2782-PEG (activated) SQ
Dalcinonacog MarzAA (FVIIa) alfa - DalcA (FIX) Factor IX Gene Therapy SQ Systemic Phase 3 in 2020 Complement Factor Xa Inhibitors Protease Engineering Platform 3 catalystbiosciences.com
Nasdaq: CBIO Pipeline Hemostasis R PC P1/2 P2 P3 SQ Marzeptacog alfa
MarzAA" - (rFVIIa) Hemophilia A or B w Inhibitors - ToB FVIID/Glanzmann/Hemlibra - ToB SQ Dalcinonacog alfa "DalcA" Hemophilia B (rFIX) FIX-Gene Therapy Hemophilia B (CB 2679d-GT) Complement IVT CB 2782-PEG
anti-C3 protease for Dry AMD SQ Systemic complement inhibitors - CB DC 4 catalystbiosciences.comNasdaq: CBIO Pipeline Hemostasis R PC P1/2 P2 P3 SQ Marzeptacog alfa MarzAA" - (rFVIIa) Hemophilia A or B w Inhibitors - ToB
FVIID/Glanzmann/Hemlibra - ToB SQ Dalcinonacog alfa "DalcA" Hemophilia B (rFIX) FIX-Gene Therapy Hemophilia B (CB 2679d-GT) Complement IVT CB 2782-PEG anti-C3 protease for Dry AMD SQ Systemic complement inhibitors - CB DC 4
catalystbiosciences.com
Nasdaq: CBIO Investment highlights Anti-C3 Dry AMD with Biogen Novel
subcutaneous factors with orphan drug designation, FVIIa SQ systemic complement MarzAA & DalcA - P2 efficacy FIX regulator research program in prophylaxis studies complete Multibillion-dollar market Experienced team opportunities 177
worldwide patents Strong balance sheet, CBIO retains full ownership $104.5 M cash - Q1 5 of all compounds 5 catalystbiosciences.comNasdaq: CBIO Investment highlights Anti-C3 Dry AMD with Biogen Novel subcutaneous factors with orphan drug
designation, FVIIa SQ systemic complement MarzAA & DalcA - P2 efficacy FIX regulator research program in prophylaxis studies complete Multibillion-dollar market Experienced team opportunities 177 worldwide patents Strong balance sheet,
CBIO retains full ownership $104.5 M cash - Q1 5 of all compounds 5 catalystbiosciences.com
Nasdaq: CBIO Addressing unmet needs in orphan bleeding disorders SQ
treatment of episodic bleeding and prophylaxis - $4B+ market Hemophilia A MarzAA & DalcA Prophylaxis w/ Inhibitors Hemophilia B Hemophilia B Hemophilia A w/ Inhibitors Acquired Factor VII Hemophilia Deficiency Glanzmann Thrombasthenia 6
catalystbiosciences.comNasdaq: CBIO Addressing unmet needs in orphan bleeding disorders SQ treatment of episodic bleeding and prophylaxis - $4B+ market Hemophilia A MarzAA & DalcA Prophylaxis w/ Inhibitors Hemophilia B Hemophilia B
Hemophilia A w/ Inhibitors Acquired Factor VII Hemophilia Deficiency Glanzmann Thrombasthenia 6 catalystbiosciences.com
Nasdaq: CBIO The Catalyst Biosciences subcutaneous solution Our highly
potent candidates + Quick & simple self-administered SQ injection + SQ dosing is the future in hemophilia, other rare hematology indications & complement mediated diseases + Significantly increases half-life + Much higher & more stable
factor levels for prophylaxis + Enables SQ treatment of bleeds + Ideal for children and adolescents 7 catalystbiosciences.comNasdaq: CBIO The Catalyst Biosciences subcutaneous solution Our highly potent candidates + Quick & simple
self-administered SQ injection + SQ dosing is the future in hemophilia, other rare hematology indications & complement mediated diseases + Significantly increases half-life + Much higher & more stable factor levels for prophylaxis + Enables
SQ treatment of bleeds + Ideal for children and adolescents 7 catalystbiosciences.com
Nasdaq: CBIO Marzeptacog alfa (activated): MarzAA rFVIIa Addresses a
clear unmet need in hemophilia & other bleeding disorders Four amino acid substitutions T128N P129A + Multiple advantages over NovoSeven RT + 9-fold higher activity vs NovoSeven RT + Potency allows for SQ dosing M298Q Only SQ bypass agent for on
demand treatment Q286R + Simple, small volume SQ administration + Improved bioavailability & prolonged half-life Increased procoagulant activity Orphan Drug Designation in US and EU 8 catalystbiosciences.comNasdaq: CBIO Marzeptacog alfa
(activated): MarzAA rFVIIa Addresses a clear unmet need in hemophilia & other bleeding disorders Four amino acid substitutions T128N P129A + Multiple advantages over NovoSeven RT + 9-fold higher activity vs NovoSeven RT + Potency allows for SQ
dosing M298Q Only SQ bypass agent for on demand treatment Q286R + Simple, small volume SQ administration + Improved bioavailability & prolonged half-life Increased procoagulant activity Orphan Drug Designation in US and EU 8
catalystbiosciences.com
Nasdaq: CBIO MarzAA Phase 2 demonstrates efficacy in prophylaxis Greater
than 90% reduction in all bleeding - Median ABR = 0 7 of 9 subjects had no bleeding at final dose level Safe & well tolerated, ~1% ISR (6/517 doses) & no ADA 12.3% 19.8 Annualized Proportion of Days Bleed Rate with Bleeding n = 9 n = 9
1.6, p = 0.009 0.8%, p = 0.009 6 m pre-treatment On treatment 6 m pre-treatment On treatment Mahlangu et al. EAHAD 2020 9 catalystbiosciences.comNasdaq: CBIO MarzAA Phase 2 demonstrates efficacy in prophylaxis Greater than 90% reduction in all
bleeding - Median ABR = 0 7 of 9 subjects had no bleeding at final dose level Safe & well tolerated, ~1% ISR (6/517 doses) & no ADA 12.3% 19.8 Annualized Proportion of Days Bleed Rate with Bleeding n = 9 n = 9 1.6, p = 0.009 0.8%, p =
0.009 6 m pre-treatment On treatment 6 m pre-treatment On treatment Mahlangu et al. EAHAD 2020 9 catalystbiosciences.com
Nasdaq: CBIO In a world of SQ prophylaxis Patients & KOLs want SQ
treatment of a bleed MarzAA has optimal properties Individuals on Hemlibra have breakthrough bleeds Fast & easy to administer Achieves therapeutic levels rapidly NovoSeven is safe but is Stops bleeding in
multiple administered IV preclinical models Can be combined with Hemlibra FEIBA should not be used with in vitro without increased Hemlibra and is given IV thrombogenicity 10 catalystbiosciences.comNasdaq: CBIO In a world of SQ prophylaxis
Patients & KOLs want SQ treatment of a bleed MarzAA has optimal properties Individuals on Hemlibra have breakthrough bleeds Fast & easy to administer Achieves therapeutic levels rapidly NovoSeven is safe but is
Stops bleeding in multiple administered IV preclinical models Can be combined with Hemlibra FEIBA should not be used with in vitro without increased Hemlibra and is given IV thrombogenicity 10 catalystbiosciences.com
Nasdaq: CBIO MarzAA P3: On demand treatment of episodic bleeding
CRIMSON-1 Registration Study - A Global Clinical Trial Opportunity in multiple Phase 1 & 2 trials Open label trial evaluating bleeding disorders demonstrated the clinical the safety & efficacy of SQ impact of SQ MarzAA MarzAA in
episodic bleeding MAA-102 rapidly achieved Primary endpoint: Hemostatic Hemophilia A or B with target activity levels efficacy using a standard inhibitors 4-point assessment scale MAA-201 demonstrated
Hemlibra breakthrough efficacy in prophylaxis, safe & ~230 bleeding episodes to be bleeds well tolerated with no ADA treated in ~75 HA/HB Factor VII deficiency individuals with inhibitors Clinically support P3 SQ
Glanzmann thrombasthenia MarzAA treatment of episodic Anticipate first patient enrolled Acquired hemophilia bleeding by end of 2020 11 catalystbiosciences.comNasdaq: CBIO MarzAA P3: On demand treatment of episodic bleeding
CRIMSON-1 Registration Study - A Global Clinical Trial Opportunity in multiple Phase 1 & 2 trials Open label trial evaluating bleeding disorders demonstrated the clinical the safety & efficacy of SQ impact of SQ MarzAA MarzAA in
episodic bleeding MAA-102 rapidly achieved Primary endpoint: Hemostatic Hemophilia A or B with target activity levels efficacy using a standard inhibitors 4-point assessment scale MAA-201 demonstrated
Hemlibra breakthrough efficacy in prophylaxis, safe & ~230 bleeding episodes to be bleeds well tolerated with no ADA treated in ~75 HA/HB Factor VII deficiency individuals with inhibitors Clinically support P3 SQ
Glanzmann thrombasthenia MarzAA treatment of episodic Anticipate first patient enrolled Acquired hemophilia bleeding by end of 2020 11 catalystbiosciences.com
Nasdaq: CBIO MarzAA development plan in 2020 Phase 3 HA/HB w Inhibitors
- ToB Phase 1/2 study in FVIID, Glanzmann & Hemlibra ToB Large commercial opportunity across multiple rare bleeding disorders Phase 1 PK/PD data support on demand as well as prophylactic treatment of bleeding Phase 2 demonstrated clinical
efficacy & tolerability for prophylaxis indications Efficacy demonstrated for SQ on demand treatment of bleeding in pre-clinical models MarzAA can be safely combined with Hemlibra in human plasma in vitro 12 catalystbiosciences.comNasdaq: CBIO
MarzAA development plan in 2020 Phase 3 HA/HB w Inhibitors - ToB Phase 1/2 study in FVIID, Glanzmann & Hemlibra ToB Large commercial opportunity across multiple rare bleeding disorders Phase 1 PK/PD data support on demand as well as
prophylactic treatment of bleeding Phase 2 demonstrated clinical efficacy & tolerability for prophylaxis indications Efficacy demonstrated for SQ on demand treatment of bleeding in pre-clinical models MarzAA can be safely combined with Hemlibra
in human plasma in vitro 12 catalystbiosciences.com
Nasdaq: CBIO Dalcinonacog alfa: novel FIX replacement for SQ delivery
Three amino acid substitutions + Increased catalytic activity + Higher affinity for FVIIIa + Resistance to antithrombin inhibition + 22-fold increased potency vs BeneFIX Differentiated from marketed IV FIXs + Simple, small volume SQ administration
R318Y + Enhanced pharmacokinetics with prolonged half-life + Excellent extravascular distribution Resistance to antithrombin T343R + Potential to maintain continuous protective levels R338E Increased FVIIIa affinity Orphan Drug Designation in US
& EU & procoagulant activity 13 catalystbiosciences.comNasdaq: CBIO Dalcinonacog alfa: novel FIX replacement for SQ delivery Three amino acid substitutions + Increased catalytic activity + Higher affinity for FVIIIa + Resistance to
antithrombin inhibition + 22-fold increased potency vs BeneFIX Differentiated from marketed IV FIXs + Simple, small volume SQ administration R318Y + Enhanced pharmacokinetics with prolonged half-life + Excellent extravascular distribution Resistance
to antithrombin T343R + Potential to maintain continuous protective levels R338E Increased FVIIIa affinity Orphan Drug Designation in US & EU & procoagulant activity 13 catalystbiosciences.com
Nasdaq: CBIO Dalcinonacog alfa phase 2b SQ clinical trial Trial
completed Initial 35 min Daily SQ Dosing to Day 28 Wash-out Post-IV Daily FIX activity levels DalcA IV DalcA SQ DalcA SQ measured for 5 days 50 IU/kg 100 IU/kg 100 IU/kg endpoint achieved with steady state FIX activity levels > 12% + Primary
endpoint: Steady state FIX + 6 severe Hemophilia B subjects dosed activity level above 12% with daily dosing + Rare propeptide mutation excluded + HLA profile associated with nAb risk was + Secondary endpoints: safety including excluded weekly ADA
testing, pharmacokinetics, pharmacodynamics, bleeding events 14 catalystbiosciences.comNasdaq: CBIO Dalcinonacog alfa phase 2b SQ clinical trial Trial completed Initial 35 min Daily SQ Dosing to Day 28 Wash-out Post-IV Daily FIX activity levels
DalcA IV DalcA SQ DalcA SQ measured for 5 days 50 IU/kg 100 IU/kg 100 IU/kg endpoint achieved with steady state FIX activity levels > 12% + Primary endpoint: Steady state FIX + 6 severe Hemophilia B subjects dosed activity level above 12% with
daily dosing + Rare propeptide mutation excluded + HLA profile associated with nAb risk was + Secondary endpoints: safety including excluded weekly ADA testing, pharmacokinetics, pharmacodynamics, bleeding events 14
catalystbiosciences.com
Nasdaq: CBIO DalcA P2b efficacy & safety demonstrated Target levels
>12% achieved with 100 IU/kg dosing for 28 Days + Dosed 6 severe HB subjects 102 withdrew on Day 7 + Steady state FIX levels up to 27% achieved after 14 days + No breakthrough bleeds + No neutralizing ADAs Target + Consistent PK profiles
Level + Terminal half-life is 2.5 - 5.1 days Wash-Out 15 catalystbiosciences.comNasdaq: CBIO DalcA P2b efficacy & safety demonstrated Target levels >12% achieved with 100 IU/kg dosing for 28 Days + Dosed 6 severe HB subjects 102
withdrew on Day 7 + Steady state FIX levels up to 27% achieved after 14 days + No breakthrough bleeds + No neutralizing ADAs Target + Consistent PK profiles Level + Terminal half-life is 2.5 - 5.1 days Wash-Out 15 catalystbiosciences.com
Nasdaq: CBIO Dalcinonacog alfa Potential to provide effective SQ
prophylaxis for individuals with Hemophilia B Phase 2b trial complete Excellent protective therapeutic FIX activity levels achieved No bleeding events during treatment demonstrates effective prophylaxis No SAEs, systemic hypersensitivity, nAb to
DalcA or wild-type FIX Mild to moderate ISR primarily with initial injections - transient & self-limiting Long half-life - demonstrates potential to lower dose / reduce dosing frequency 16 catalystbiosciences.comNasdaq: CBIO
Dalcinonacog alfa Potential to provide effective SQ prophylaxis for individuals with Hemophilia B Phase 2b trial complete Excellent protective therapeutic FIX activity levels achieved No bleeding events during treatment demonstrates effective
prophylaxis No SAEs, systemic hypersensitivity, nAb to DalcA or wild-type FIX Mild to moderate ISR primarily with initial injections - transient & self-limiting Long half-life - demonstrates potential to lower dose / reduce dosing